| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | ||||
| | |||||||
| | | | | | | ||
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | | | ||
| | | | | 4 | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | 6 | | | |
| | | | | | | ||
| | | | | 7 | | | |
| | | | | | | ||
| | | | | 8 | | | |
| | | | | ||||
| | |||||||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | 17 | | | |
| | | | | 18 | | |
| ||||||||
| | | | | | |||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| ||||||||
| | | | |||||
| | |||||||
| | | | | | |
Proposal | | | Voting Choices and Board Recommendation | |
Proposal 1: Election of Directors | | | • vote in favor of all nominees; | |
| • withhold authority to vote for all nominees; or | | ||
| • withhold authority to vote for any specified nominee. | | ||
| The Board recommends a vote FOR each of the nominees. | | ||
Proposal 2: Approval of an amendment | | | • vote in favor of | |
| • vote against | | ||
| • abstain from voting on | | ||
| The Board recommends a vote FOR approval. | | ||
Proposal 3: | ||||
| | • vote in favor of ratification; | | |
| • vote against ratification; or | | ||
| • abstain from voting on ratification. | | ||
| The Board recommends a vote FOR ratification. | | ||
Proposal | | | • vote in favor of proposal; | |
| • vote against proposal; or | | ||
| • abstain from voting on proposal. | | ||
| The Board recommends a vote FOR the advisory vote to approve executive compensation. | |
Proposal | | | | | Abstentions and Broker Non-Votes | | |
Proposal 1: Election of Directors | | | | | | ||
Proposal 2: Approval of an amendment | | | | | | ||
Proposal 3: | |||||||
| | | | | |||
Proposal | | | | | |
| | | Timothy C. Barabe (1) | | | Susan L. Kelley (3) | | | Ronald M. Lindsay (3) | | | Michael D. Loberg (2)(3) | | | William G. Messenger (1)(2) | | | Ran Nussbaum | | | Paolo Pucci | | | Patrick J. Zenner (1)(2) | | ||||||||||||||||||||||||
High level of financial literacy | | | | | X | | | | | | | | | | | | | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | |
Relevant biotechnology business experience | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | |
Extensive knowledge of drug research and development | | | | | | | | | | | X | | | | | | X | | | | | | X | | | | | | | | | | | | X | | | | | | X | | | | | | X | | |
Extensive knowledge of drug commercialization and marketing | | | | | | | | | | | | | | | | | X | | | | | | X | | | | | | | | | | | | | | | | | | X | | | | | | X | | |
Expertise in corporate governance and | | | | | X | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | |
Diversity of background, professional experience or culture | | | | | X | | | | | | X | | | | | | | | | | | | X | | | | | | X | | | | | | X | | | | | | X | | | | | | | | |
Name | | Fees Earned or Paid in Cash ($) | | Option Awards(1)($) | | Total ($) | | | Fees Earned or Paid in Cash ($) | | Option Awards(1) ($) | | Total ($) | | ||||||||||||||||||||||||
Timothy C. Barabe | | | $ | 57,000 | | | | $ | 14,060 | | | | $ | 71,060 | | | | | $ | 60,250 | | | | $ | 32,188 | | | | $ | 92,438 | | | ||||||
Susan L. Kelley, M.D. | | | | 49,500 | | | | | 14,060 | | | | | 63,560 | | | | | | 54,000 | | | | | 32,188 | | | | | 86,188 | | | ||||||
Ronald M. Lindsay, Ph.D. . | | | | 67,000 | | | | | 14,060 | | | | | 81,060 | | | ||||||||||||||||||||||
Michael D. Loberg, Ph.D.(3) | | | | 55,750 | | | | | 14,060 | | | | | 69,810 | | | ||||||||||||||||||||||
Ronald M. Lindsay, Ph.D. | | | | 74,000 | | | | | 32,188 | | | | | 106,188 | | | ||||||||||||||||||||||
Michael D. Loberg, Ph.D | | | | 59,000 | | | | | 32,188 | | | | | 91,188 | | | ||||||||||||||||||||||
William G. Messenger, D. Min. | | | | 64,500 | | | | | 14,060 | | | | | 78,560 | | | | | | 65,250 | | | | | 32,188 | | | | | 97,438 | | | ||||||
Ran Nussbaum | | | | 6,250 | | | | | 18,459 | | | | | 24,709 | | | | | | 39,000 | | | | | 32,188 | | | | | 71,188 | | | ||||||
Patrick J. Zenner | | | | 69,500 | | | | | 17,575 | | | | | 87,075 | | | | | | 70,250 | | | | | 40,235 | | | | | 110,485 | | |
| Agenus Inc. | | | Eloxx Pharmaceuticals, Inc. | | | Mirati Therapeutics, Inc. | |
| Athersys, Inc. | | | Endocyte Inc. | | | Rigel Pharmaceuticals, Inc. | |
| AVEO Pharmaceuticals, Inc. | | | Epizyme, Inc. | | | Spring Bank Pharmaceuticals, Inc. | |
| Calithera Biosciences, Inc. | | | Geron Corporation | | | Sunesis Pharmaceutical, Inc. | |
| ChemoCentryx, Inc. | | | GTx, Inc. | | | Syndax Pharmaceuticals, Inc. | |
| CTI BioPharma Corp | | | Infinity Pharmaceuticals, Inc. | | | Verastem, Inc. | |
| Cytokinetics, Incorporated | | | Karyopharm Therapeutics Inc. | | | Ziopharm Oncology, Inc. | |
Name and Principal Position | | 2016 Annualized Base Salary ($) | | 2017 Annualized Base Salary ($) | | % Increase | | Comment | | | 2017 Annualized Base Salary ($) | | 2018 Annualized Base Salary ($) | | % Increase | | Comment | | ||||||||||||||||||||||||||
Paolo Pucci, CEO | | | | 489,000 | | | | | 499,000 | | | | | 2.0 | | | Base salary negotiated in and adjusted per amended employment agreement and annual review. | | | | | 499,000 | | | | | 506,000 | | | | | 1.5 | | | Base salary negotiated in and adjusted per amended employment agreement and annual review. | | ||||||||
Peter S. Lawrence, COO | | | | 431,000 | | | | | 448,000 | | | | | 4.0 | | | Base salary negotiated in and adjusted per amended employment agreement and annual review. | | | | | 448,000 | | | | | 459,000 | | | | | 2.5 | | | Base salary negotiated in and adjusted per amended employment agreement and annual review. | | ||||||||
Dr. Brian Schwartz, CMO | | | | 429,000 | | | | | 446,000 | | | | | 4.0 | | | Base salary negotiated in and adjusted per employment agreement and annual review. | | | | | 446,000 | | | | | 457,000 | | | | | 2.5 | | | Base salary negotiated in and adjusted per employment agreement and annual review. | | ||||||||
Robert J. Weiskopf, CFO | | | | 305,000 | | | | | 317,000 | | | | | 4.0 | | | Base salary adjusted at annual review. | | | | | 317,000 | | | | | 325,000 | | | | | 2.5 | | | Base salary adjusted at annual review. | |
Name and Principal Position | | | 2018 Bonus Target (% of Base Salary) | | | 2018 Bonus Actual (% of Base Salary) | | | Comment | |
Paolo Pucci, CEO | | | 60.0% | | | 60.0% | | | Target bonus set by terms of amended employment agreement. | |
Peter S. Lawrence, COO | | | 45.0% | | | 45.0% | | | Target bonus set by terms of amended employment agreement. | |
Dr. Brian Schwartz, CMO | | | 40.0% | | | 40.0% | | | Target bonus set by terms of employment agreement. | |
Robert J. Weiskopf, CFO | | | 40.0% | | | 40.0% | | | Bonus target set by Compensation Committee in accordance with annual process. | |
Name and Principal Position | | Year | | Salary ($) (1) | | Bonus ($) | | Stock Awards ($) | | Option Awards ($) (2) | | Non-Equity Incentive Plan Compensation ($) (3) | | All Other Compensation ($) (4) | | Total ($) | | Year | | Salary ($)(1) | | Bonus ($) | | Stock Awards ($) | | Option Awards ($)(2) | | Non-Equity Incentive Plan Compensation ($)(3) | | All Other Compensation ($)(4) | | Total ($) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Paolo Pucci Chief Executive Officer | | | | | 2017 | | | | | 498,718 | | | | | — | | | | | — | | | | | 634,860 | | | | | 248,568 | | | | | 8,742 | | | | | 1,390,888 | | | | | 2018 | | | | | 506,302 | | | | | — | | | | | — | | | | | 925,512 | | | | | 303,971 | | | | | 8,742 | | | | | 1,744,527 | ||||||||||||||
| | | 2016 | | | | | 489,345 | | | | | — | | | | | — | | | | | 548,208 | | | | | 255,438 | | | | | 8,550 | | | | | 1,301,541 | | | | 2017 | | | | | 498,718 | | | | | — | | | | | — | | | | | 634,860 | | | | | 248,568 | | | | | 8,742 | | | | | 1,390,888 | |||||||||||||||||
| | | 2015 | | | | | 489,345 | | | | | — | | | | | — | | | | | 285,948 | | | | | 293,607 | | | | | 8,550 | | | | | 1,077,450 | | | | 2016 | | | | | 489,345 | | | | | — | | | | | — | | | | | 548,208 | | | | | 255,438 | | | | | 8,550 | | | | | 1,301,541 | |||||||||||||||||
Peter S. Lawrence President, Chief Operating Officer, General Counsel and Secretary | | | | | 2017 | | | | | 447,140 | | | | | — | | | | | — | | | | | 350,267 | | | | | 167,279 | | | | | 8,742 | | | | | 973,428 | | | | | 2018 | | | | | 458,591 | | | | | — | | | | | — | | | | | 494,626 | | | | | 206,579 | | | | | 8,742 | | | | | 1,168,538 | ||||||||||||||
| | | 2016 | | | | | 430,286 | | | | | — | | | | | — | | | | | 274,104 | | | | | 168,597 | | | | | 8,550 | | | | | 881,536 | | | | 2017 | | | | | 447,140 | | | | | — | | | | | — | | | | | 350,267 | | | | | 167,279 | | | | | 8,742 | | | | | 973,428 | |||||||||||||||||
| | | 2015 | | | | | 421,562 | | | | | — | | | | | — | | | | | 160,571 | | | | | 189,990 | | | | | 8,550 | | | | | 780,673 | | | | 2016 | | | | | 430,286 | | | | | — | | | | | — | | | | | 274,104 | | | | | 168,597 | | | | | 8,550 | | | | | 881,536 | |||||||||||||||||
Dr. Brian Schwartz Chief Medical Officer and Senior Vice President | | | | | 2017 | | | | | 445,121 | | | | | — | | | | | — | | | | | 275,106 | | | | | 148,021 | | | | | 8,742 | | | | | 876,991 | | | | | 2018 | | | | | 456,521 | | | | | — | | | | | — | | | | | 409,554 | | | | | 182,797 | | | | | 8,742 | | | | | 1,057,614 | ||||||||||||||
| | | 2016 | | | | | 428,001 | | | | | — | | | | | — | | | | | 237,557 | | | | | 149,187 | | | | | 8,550 | | | | | 823,295 | | | | 2017 | | | | | 445,121 | | | | | — | | | | | — | | | | | 275,106 | | | | | 148,021 | | | | | 8,742 | | | | | 876,991 | |||||||||||||||||
| | | 2015 | | | | | 410,991 | | | | | — | | | | | — | | | | | 107,780 | | | | | 164,884 | | | | | 8,550 | | | | | 692,205 | | | | 2016 | | | | | 428,001 | | | | | — | | | | | — | | | | | 237,557 | | | | | 149,187 | | | | | 8,550 | | | | | 823,295 | |||||||||||||||||
Robert J. Weiskopf Chief Financial Officer and Treasurer | | | | | 2017 | | | | | 316,684 | | | | | — | | | | | — | | | | | 183,369 | | | | | 105,310 | | | | | 8,742 | | | | | 614,105 | | | | | 2018 | | | | | 324,795 | | | | | — | | | | | — | | | | | 92,336 | | | | | 130,052 | | | | | 8,742 | | | | | 555,925 | ||||||||||||||
| | | 2016 | | | | | 305,000 | | | | | — | | | | | — | | | | | 137,052 | | | | | 92,873 | | | | | 8,550 | | | | | 543,475 | | | | 2017 | | | | | 316,684 | | | | | — | | | | | — | | | | | 183,369 | | | | | 105,310 | | | | | 8,742 | | | | | 614,105 | |||||||||||||||||
| | | 2015 | | | | | 288,372 | | | | | — | | | | | — | | | | | 91,876 | | | | | 106,750 | | | | | 8,550 | | | | | 495,548 | | | | 2016 | | | | | 305,000 | | | | | — | | | | | — | | | | | 137,052 | | | | | 92,873 | | | | | 8,550 | | | | | 543,475 |
| | | | | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards(1) | | | All Other Option Awards: Number of Securities Underlying Options (#) | | Grant Date Fair Value of Stock and Option Awards ($) | | | | | | | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards(1) | | | All Other Option Awards: Number of Securities Underlying Options (#) | | Exercise or base price of option awards ($/Sh) | | Grant Date Fair Value of Stock and Option Awards ($) | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | | Grant Date | | Threshold ($) | | Target ($) | | Maximum ($) | | | | Grant Date | | Threshold ($) | | Target ($) | | Maximum ($) | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Paolo Pucci | | | | N/A | | | | | — | | | | | 303,971 | | | | | 455,957 | | | | | | | | | | | | | | | | | N/A | | | | | — | | | | | 316,130 | | | | | 474,195 | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | 01/17/2017 | | | | | | | | | | | | | | | | | | | | 300,000 | | | | | 281,460 | | | | | | | 01/16/2018 | | | | | | | | | | | | | | | | | | | | 249,000 | | | | | 1.75 | | | | | 262,172 | | | | ||||||||||||||||||||||||||||||||||||||
| | | | 04/04/2017 | | | | | | | | | | | | | | | | | | | | 600,000 | | | | | 353,400 | | | | | | | 05/08/2018 | | | | | | | | | | | | | | | | | | | | 80,000 | | | | | 2.48 | | | | | 127,480 | | | | ||||||||||||||||||||||||||||||||||||||
| | | | 07/23/2018 | | | | | | | | | | | | | | | | | | | | 150,000 | | | | | 5.48 | | | | | 535,860 | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Peter S. Lawrence | | | | N/A | | | | | — | | | | | 206,579 | | | | | 309,869 | | | | | | | | | | | | | | | | | N/A | | | | | — | | | | | 214,842 | | | | | 322,264 | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | 01/16/2018 | | | | | | | | | | | | | | | | | | | | 124,500 | | | | | 1.75 | | | | | 131,086 | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 01/17/2017 | | | | | | | | | | | | | | | | | | | | 185,000 | | | | | 173,567 | | | | | | | 05/08/2018 | | | | | | | | | | | | | | | | | | | | 60,000 | | | | | 2.48 | | | | | 95,610 | | | | ||||||||||||||||||||||||||||||||||||||
| | | | 04/04/2017 | | | | | | | | | | | | | | | | | | | | 300,000 | | | | | 176,700 | | | | | | | 07/23/2018 | | | | | | | | | | | | | | | | | | | | 75,000 | | | | | 5.48 | | | | | 267,930 | | | | ||||||||||||||||||||||||||||||||||||||
Dr. Brian Schwartz | | | | N/A | | | | | — | | | | | 182,797 | | | | | 274,195 | | | | | | | | | | | | | | | | | N/A | | | | | — | | | | | 190,109 | | | | | 285,164 | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | 01/17/2017 | | | | | | | | | | | | | | | | | | | | 130,000 | | | | | 121,966 | | | | | | | 01/16/2018 | | | | | | | | | | | | | | | | | | | | 107,900 | | | | | 1.75 | | | | | 113,608 | | | | ||||||||||||||||||||||||||||||||||||||
| | | | 04/04/2017 | | | | | | | | | | | | | | | | | | | | 260,000 | | | | | 153,140 | | | | | | | 05/08/2018 | | | | | | | | | | | | | | | | | | | | 40,000 | | | | | 2.48 | | | | | 63,740 | | | | ||||||||||||||||||||||||||||||||||||||
| | | | 07/23/2018 | | | | | | | | | | | | | | | | | | | | 65,000 | | | | | 5.48 | | | | | 232,206 | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Robert J. Weiskopf | | | | N/A | | | | | — | | | | | 130,052 | | | | | 195,078 | | | | | | | | | | | | | | | | | N/A | | | | | — | | | | | 130,052 | | | | | 195,078 | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||
| | | | 01/17/2017 | | | | | | | | | | | | | | | | | | | | 95,000 | | | | | 89,129 | | | | | | | 01/16/2018 | | | | | | | | | | | | | | | | | | | | 62,250 | | | | | 1.75 | | | | | 65,543 | | | | ||||||||||||||||||||||||||||||||||||||
| | | | 04/04/2017 | | | | | | | | | | | | | | | | | | | | 150,000 | | | | | 88,350 | | | | | | | 07/23/2018 | | | | | | | | | | | | | | | | | | | | 7,500 | | | | | 5.48 | | | | | 26,793 | | | | ||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Name | | Number of Securities Underlying Unexercised Options (#)(1) Exercisable | | Number of Securities Underlying Unexercised Options (#)(1) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | Equity Incentive Plan Awards: Number of Shares, Units or Other Rights that Have Not Vested | | Equity Incentive Plan Awards: Market or Payout Value of Shares, Units or Other Rights that Have Not Vested(2) | | | Number of Securities Underlying Unexercised Options (#)(1) Exercisable | | Number of Securities Underlying Unexercised Options (#)(1) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | ||||||||||||||||||||||||||||||||||
Paolo Pucci | | | | 500,000 | | | | | | | | | $ | 3.95 | | | | | 6/9/2018 | | | | | | | | | | 225,000 | | | | | | | | | $ | 3.42 | | | | | 1/21/2020 | | | ||||||||||
| | | | 225,000 | | | | | | | | | | 3.42 | | | | | 1/21/2020 | | | | | | | | | | 100,000 | | | | | | | | | | 4.14 | | | | | 7/15/2020 | | | ||||||||||
| | | | 100,000 | | | | | | | | | | 4.14 | | | | | 7/15/2020 | | | | | | | | | | 300,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | ||||||||||
| | | | 300,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | | | | 315,000 | | | | | | | | | | 7.95 | | | | | 2/1/2022 | | | ||||||||||
| | | | 315,000 | | | | | | | | | | 7.95 | | | | | 2/1/2022 | | | | | | | | | | 285,000 | | | | | | | | | | 2.51 | | | | | 1/14/2023 | | | ||||||||||
| | | | 285,000 | | | | | | | | | | 2.51 | | | | | 1/14/2023 | | | | | | | | | | 305,000 | | | | | | | | | | 2.57 | | | | | 1/22/2024 | | | ||||||||||
| | | | 228,750 | | | | | 76,250 | | | | | 2.57 | | | | | 1/22/2024 | | | | | | | | | | 195,002 | | | | | 97,500 | | | | | 1.16 | | | | | 1/20/2025 | | | ||||||||||
| | | | 97,502 | | | | | 195,000 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | | | | 240,000 | | | | | 240,000 | | | | | 1.79 | | | | | 1/19/2026 | | | ||||||||||
| | | | 120,000 | | | | | 360,000 | | | | | 1.79 | | | | | 1/19/2026 | | | | | | | | | | 75,000 | | | | | 225,000 | | | | | 1.53 | | | | | 1/17/2027 | | | ||||||||||
| | | | | | | | | 300,000 | | | | | 1.53 | | | | | 1/17/2027 | | | | | | | | | | | | | | | 600,000 | | | | | 0.95 | | | | | 4/4/2027 | | | ||||||||||
| | | | | | | | | 600,000 | | | | | 0.95 | | | | | 4/4/2027 | | | | | | | | | | | | | | | 249,000 | | | | | 1.75 | | | | | 1/16/2028 | | | ||||||||||
| | | | | | | | | 80,000 | | | | | 2.48 | | | | | 5/8/2028 | | | |||||||||||||||||||||||||||||||||||
| | | | | | | | | 150,000 | | | | | 5.48 | | | | | 7/23/2028 | | | |||||||||||||||||||||||||||||||||||
Peter S. Lawrence | | | | 200,000 | | | | | | | | | | 4.75 | | | | | 1/17/2018 | | | | | | | | | | 130,000 | | | | | | | | | | 3.42 | | | | | 1/21/2020 | | | ||||||||||
| | | | 130,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | |||||||||||||||||||||||||||||||||||
| | | | 25,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | |||||||||||||||||||||||||||||||||||
| | | | 130,000 | | | | | | | | | | 3.42 | | | | | 1/21/2020 | | | | | | | | | | 147,750 | | | | | | | | | | 7.95 | | | | | 2/1/2022 | | | ||||||||||
| | | | 130,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | | | | 123,500 | | | | | | | | | | 2.51 | | | | | 1/14/2023 | | | ||||||||||
| | | | 25,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | | | | 140,500 | | | | | | | | | | 2.57 | | | | | 1/22/2024 | | | ||||||||||
| | | | 147,750 | | | | | | | | | | 7.95 | | | | | 2/1/2022 | | | | | | | | | | 126,750 | | | | | 42,250 | | | | | 1.16 | | | | | 1/20/2025 | | | ||||||||||
| | | | 123,500 | | | | | | | | | | 2.51 | | | | | 1/14/2023 | | | | | | | | | | 37,500 | | | | | 12,500 | | | | | 1.16 | | | | | 1/20/2025 | | | ||||||||||
| | | | 105,375 | | | | | 35,125 | | | | | 2.57 | | | | | 1/22/2024 | | | | | | | | | | 120,000 | | | | | 120,000 | | | | | 1.79 | | | | | 1/19/2026 | | | ||||||||||
| | | | 84,500 | | | | | 84,500 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | | | | 37,500 | | | | | 112,500 | | | | | 1.53 | | | | | 1/17/2027 | | | ||||||||||
| | | | 25,000 | | | | | 25,000 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | | | | 8,750 | | | | | 26,250 | | | | | 1.53 | | | | | 1/17/2027 | | | ||||||||||
| | | | 60,000 | | | | | 180,000 | | | | | 1.79 | | | | | 1/19/2026 | | | | | | | | | | | | | | | 300,000 | | | | | 0.95 | | | | | 4/4/2027 | | | ||||||||||
| | | | | | | | | 150,000 | | | | | 1.53 | | | | | 1/17/2027 | | | | | | | | | | | | | | | 124,500 | | | | | 1.75 | | | | | 1/16/2028 | | | ||||||||||
| | | | | | | | | 35,000 | | | | | 1.53 | | | | | 1/17/2027 | | | | | | | | | | | | | | | 60,000 | | | | | 2.48 | | | | | 5/8/2028 | | | ||||||||||
| | | | | | | | | 300,000 | | | | | 0.95 | | | | | 4/4/2027 | | | | | | | | | | | | | | | 75,000 | | | | | 5.48 | | | | | 7/23/2028 | | | ||||||||||
Dr. Brian Schwartz | | | | 200,000 | | | | | | | | | | 3.62 | | | | | 7/14/2018 | | | | | | | | | | 90,000 | | | | | | | | | | 3.42 | | | | | 1/21/2020 | | | ||||||||||
| | | | 90,000 | | | | | | | | | | 3.42 | | | | | 1/21/2020 | | | | | | | | | | 90,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | ||||||||||
| | | | 90,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | | | | 50,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | ||||||||||
| | | | 50,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | | | | 109,500 | | | | | | | | | | 7.95 | | | | | 2/1/2022 | | | ||||||||||
| | | | 109,500 | | | | | | | | | | 7.95 | | | | | 2/1/2022 | | | | | | | | | | 85,500 | | | | | | | | | | 2.51 | | | | | 1/14/2023 | | | ||||||||||
| | | | 85,500 | | | | | | | | | | 2.51 | | | | | 1/14/2023 | | | | | | | | | | 106,500 | | | | | | | | | | 2.57 | | | | | 1/22/2024 | | | ||||||||||
| | | | 79,875 | | | | | 26,625 | | | | | 2.57 | | | | | 1/22/2024 | | | | | | | | | | 87,750 | | | | | 29,250 | | | | | 1.16 | | | | | 1/20/2025 | | | ||||||||||
| | | | 58,500 | | | | | 58,500 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | | | | 22,500 | | | | | 7,500 | | | | | 1.16 | | | | | 1/20/2025 | | | ||||||||||
| | | | 15,000 | | | | | 15,000 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | | | | 104,000 | | | | | 104,000 | | | | | 1.79 | | | | | 1/19/2026 | | | ||||||||||
| | | | 52,000 | | | | | 156,000 | | | | | 1.79 | | | | | 1/19/2026 | | | | | | | | | | 32,500 | | | | | 97,500 | | | | | 1.53 | | | | | 1/17/2027 | | | ||||||||||
| | | | | | | | | 130,000 | | | | | 1.53 | | | | | 1/17/2027 | | | | | | | | | | | | | | | 260,000 | | | | | 0.95 | | | | | 4/4/2027 | | | ||||||||||
| | | | | | | | | 260,000 | | | | | 0.95 | | | | | 4/4/2027 | | | | | | | | | | | | | | | 107,900 | | | | | 1.75 | | | | | 1/16/2028 | | | ||||||||||
| | | | | | | | | 40,000 | | | | | 2.48 | | | | | 5/8/2028 | | | |||||||||||||||||||||||||||||||||||
| | | | | | | | | 65,000 | | | | | 5.48 | | | | | 7/23/2028 | | |
Name | | Number of Securities Underlying Unexercised Options (#)(1) Exercisable | | Number of Securities Underlying Unexercised Options (#)(1) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | Equity Incentive Plan Awards: Number of Shares, Units or Other Rights that Have Not Vested | | Equity Incentive Plan Awards: Market or Payout Value of Shares, Units or Other Rights that Have Not Vested(2) | | | Number of Securities Underlying Unexercised Options (#)(1) Exercisable | | Number of Securities Underlying Unexercised Options (#)(1) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | ||||||||||||||||||||||||||||||||||
Robert J. Weiskopf | | | | 22,500 | | | | | | | | | | 4.75 | | | | | 1/17/2018 | | | | | | | | | | 45,000 | | | | | | | | | | 3.42 | | | | | 1/21/2020 | | | ||||||||||
| | | | 45,000 | | | | | | | | | | 3.42 | | | | | 1/21/2020 | | | | | | | | | | 45,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | ||||||||||
| | | | 45,000 | | | | | | | | | | 6.70 | | | | | 1/24/2021 | | | | | | | | | | 40,500 | | | | | | | | | | 7.95 | | | | | 2/01/2022 | | | ||||||||||
| | | | 40,500 | | | | | | | | | | 7.95 | | | | | 2/01/2022 | | | | | | | | | | 42,750 | | | | | | | | | | 2.51 | | | | | 1/14/2023 | | | ||||||||||
| | | | 42,750 | | | | | | | | | | 2.51 | | | | | 1/14/2023 | | | | | | | | | | 48,250 | | | | | | | | | | 2.57 | | | | | 1/22/2024 | | | ||||||||||
| | | | 36,187 | | | | | 12,063 | | | | | 2.57 | | | | | 1/22/2024 | | | | | | | | | | 43,875 | | | | | 14,625 | | | | | 1.16 | | | | | 1/20/2025 | | | ||||||||||
| | | | 29,250 | | | | | 29,250 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | | | | 15,000 | | | | | 5,000 | | | | | 1.16 | | | | | 1/20/2025 | | | ||||||||||
| | | | 10,000 | | | | | 10,000 | | | | | 1.16 | | | | | 1/20/2025 | | | | | | | | | | 22,500 | | | | | 7,500 | | | | | 1.80 | | | | | 6/01/2025 | | | ||||||||||
| | | | 15,000 | | | | | 15,000 | | | | | 1.80 | | | | | 6/01/2025 | | | | | | | | | | 60,000 | | | | | 60,000 | | | | | 1.79 | | | | | 1/19/2026 | | | ||||||||||
| | | | 30,000 | | | | | 90,000 | | | | | 1.79 | | | | | 1/19/2026 | | | | | | | | | | 18,750 | | | | | 56,250 | | | | | 1.53 | | | | | 1/17/2027 | | | ||||||||||
| | | | | | | | | 75,000 | | | | | 1.53 | | | | | 1/17/2027 | | | | | | | | | | 5,000 | | | | | 15,000 | | | | | 1.53 | | | | | 1/17/2027 | | | ||||||||||
| | | | | | | | | 20,000 | | | | | 1.53 | | | | | 1/17/2027 | | | | | | | | | | | | | | | 160,000 | | | | | 0.95 | | | | | 4/4/2027 | | | ||||||||||
| | | | | | | | | 160,000 | | | | | 0.95 | | | | | 4/4/2027 | | | | | | | | | | | | | | | 62,250 | | | | | 1.75 | | | | | 1/16/2028 | | | ||||||||||
| | | | | | | | | 7,500 | | | | | 5.48 | | | | | 7/23/2028 | | |
Name | | | Number of Securities Acquired on Exercise | | | Value Realized Upon Exercise ($) | | | Number of Shares Acquired on Vesting | | | Value Realized on Vesting ($)(1) | | ||||||||||||
Peter S. Lawrence | | | | | — | | | | | | — | | | | | | 6,250 | | | | | | 9,875 | | |
Dr. Brian Schwartz | | | | | — | | | | | | — | | | | | | 7,500 | | | | | | 11,850 | | |
Robert J. Weiskopf | | | | | — | | | | | | — | | | | | | 3,200 | | | | | | 5,056 | | |
Name | | | Number of Securities Acquired on Exercise | | | Value Realized Upon Exercise ($) | | ||||||
Paolo Pucci | | | | | 500,000 | | | | | | 2,861,519 | | |
Dr. Brian Schwartz | | | | | 200,000 | | | | | | 1,036,000 | | |
Name | | Cash Payment(1) ($) | | Equity Acceleration ($) | | Benefits and Perquisites(2) ($) | | Total ($) | | | Cash Payment(1) ($) | | Equity Acceleration ($) | | Benefits and Perquisites(2) ($) | | Total ($) | | ||||||||||||||||||||||||||||||||
Paolo Pucci | | | $ | 1,540,439 | | | | $ | 551,550 | | | | $ | 48,870 | | | | $ | 2,140,859 | | | | | $ | 1,555,413 | | | | $ | 2,040,355 | | | | $ | 51,261 | | | | $ | 3,647,029 | | | ||||||||
Peter S. Lawrence | | | | 649,410 | | | | | 285,855 | | | | | 24,435 | | | | | 959,700 | | | | | | 627,003 | | | | | 1,068,188 | | | | | 25,630 | | | | | 1,720,821 | | | ||||||||
Dr. Brian Schwartz | | | | 624,186 | | | | | 233,615 | | | | | 24,435 | | | | | 882,236 | | | | | | 605,597 | | | | | 876,846 | | | | | 25,630 | | | | | 1,508,073 | | |
| | 2017 | | 2016 | | | 2018 | | 2017 | | ||||||||||||||||
Audit Fees | | | $ | 544,000 | | | | $ | 490,000 | | | | | $ | 562,000 | | | | $ | 544,000 | | | ||||
Audit-Related Fees | | | | — | | | | | — | | | | | | — | | | | | — | | | ||||
Tax Fees | | | | — | | | | | — | | | | | | — | | | | | — | | | ||||
All Other Fees | | | | — | | | | | — | | | | | | — | | | | | — | | | ||||
Total | | | $ | 544,000 | | | | $ | 490,000 | | | | | $ | 562,000 | | | | $ | 544,000 | | | |
Name | | | Common Stock Owned | | | Options to Purchase Common Stock | | | Total Stock and Stock-based Holdings | | | Percent of Class | | ||||||||||||
First Eagle Investment Management, LLC(1) 1345 Avenue of the Americas New York, NY 10105 | | | | | 14,733,484 | | | | | | — | | | | | | 14,733,484 | | | | | | 16.9% | | |
Nantahala Capital Management, LLC(2) 19 Old Kings Highway S, Suite 200 Darien, CT 06820 | | | | | 12,222,130 | | | | | | — | | | | | | 12,222,130 | | | | | | 14.0% | | |
BVF Partners, LP(3) 900 North Michigan Avenue, Suite 1100 Chicago, IL 60611 | | | | | 16,434,912 | | | | | | — | | | | | | 16,434,912 | | | | | | 18.9% | | |
Name | | | Common Stock Owned | | | Warrants to Purchase Common Stock | | | Options to Purchase Common Stock | | | Total Shares Beneficially Owned | | | Percent of Class | | |||||||||||||||
First Eagle Investment Management, LLC (1) 1345 Avenue of the Americas, New York, NY 10105 | | | | | 16,081,128 | | | | | | | | | | | | | | | | | | 16,081,128 | | | | | | 14.7% | | |
Nantahala Capital Management, LLC(2) 19 Old Kings Highway S, Suite 200, Darien, CT 06820 | | | | | 12,101,879 | | | | | | 535,242 | | | | | | | | | | | | 12,637,121 | | | | | | 11.5% | | |
BlackRock, Inc.(3) 55 East 52nd Street, New York, NY 10055 | | | | | 8,618,012 | | | | | | | | | | | | | | | | | | 8,618,012 | | | | | | 7.9% | | |
BVF Inc.(4) 44 Montgomery St., 40th Floor San Francisco, California 94104 | | | | | 6,230,418 | | | | | | 2,439,932 | | | | | | | | | | | | 8,670,350 | | | | | | 7.8% | | |
Pontifax Group(5) 14 Shenkar Street Herzliya Pituach 46140, Israel | | | | | 6,798,429 | | | | | | 1,784,000 | | | | | | 30,000 | | | | | | 8,612,429 | | | | | | 7.8% | | |
Vanguard Group(6) 100 Vanguard Blvd, Malvern, PA 19355 | | | | | 5,465,858 | | | | | | | | | | | | | | | | | | 5,465,858 | | | | | | 5.0% | | |
Directors and Executive Officers(1) | | | Common Stock Owned | | | Options to Purchase Common Stock | | | Total Stock and Stock-based Holdings | | | Percent of Class | | ||||||||||||
Timothy C. Barabe(2) | | | | | 136,897 | | | | | | 130,000 | | | | | | 266,897 | | | | | | * | | |
Susan L. Kelley | | | | | 50,000 | | | | | | 125,000 | | | | | | 175,000 | | | | | | * | | |
Ronald M. Lindsay | | | | | 20,000 | | | | | | 130,000 | | | | | | 150,000 | | | | | | * | | |
Michael D. Loberg | | | | | 162,514 | | | | | | 130,000 | | | | | | 292,514 | | | | | | * | | |
William G. Messenger | | | | | 10,000 | | | | | | 130,000 | | | | | | 140,000 | | | | | | * | | |
Ran Nussbaum(3) | | | | | — | | | | | | — | | | | | | — | | | | | | * | | |
Patrick J. Zenner | | | | | 73,770 | | | | | | 205,000 | | | | | | 278,770 | | | | | | * | | |
Peter S. Lawrence | | | | | 77,743 | | | | | | 1,027,250 | | | | | | 1,104,993 | | | | | | 1.3% | | |
Paolo Pucci | | | | | 485,364 | | | | | | 2,540,002 | | | | | | 3,025,366 | | | | | | 3.5% | | |
Brian Schwartz | | | | | 63,886 | | | | | | 978,250 | | | | | | 1,042,136 | | | | | | 1.2% | | |
Robert J. Weiskopf | | | | | 30,407 | | | | | | 379,125 | | | | | | 409,532 | | | | | | * | | |
Directors and executive officers as a group (11 persons) | | | | | 1,110,581 | | | | | | 5,774,627 | | | | | | 6,885,208 | | | | | | 7.9% | | |
|
Directors and Executive Officers(1) | | | Common Stock Owned | | | Options to Purchase Common Stock | | | Warrants to Purchase Common Stock | | | Total Shares Beneficially Owned | | | Percent of Class | | |||||||||||||||
Timothy C. Barabe(2) | | | | | 136,897 | | | | | | 160,000 | | | | | | | | | | | | 296,897 | | | | | | * | | |
Susan L. Kelley | | | | | 50,000 | | | | | | 165,000 | | | | | | | | | | | | 215,000 | | | | | | * | | |
Ronald M. Lindsay | | | | | 50,800 | | | | | | 160,000 | | | | | | | | | | | | 210,800 | | | | | | * | | |
Michael D. Loberg | | | | | 162,514 | | | | | | 160,000 | | | | | | | | | | | | 322,514 | | | | | | * | | |
William G. Messenger | | | | | 10,000 | | | | | | 160,000 | | | | | | | | | | | | 170,000 | | | | | | * | | |
Ran Nussbaum(3) | | | | | 6,798,429 | | | | | | 30,000 | | | | | | 1,784,000 | | | | | | 8,612,429 | | | | | | 7.8% | | |
Patrick J. Zenner | | | | | 82,216 | | | | | | 240,000 | | | | | | | | | | | | 322,216 | | | | | | * | | |
Peter S. Lawrence | | | | | 77,743 | | | | | | 1,234,375 | | | | | | | | | | | | 1,312,118 | | | | | | 1.2% | | |
Paolo Pucci | | | | | 699,378 | | | | | | 2,364,752 | | | | | | | | | | | | 3,064,130 | | | | | | 2.7% | | |
Brian Schwartz | | | | | 115,317 | | | | | | 936,475 | | | | | | | | | | | | 1,051,792 | | | | | | 1.0% | | |
Robert J. Weiskopf | | | | | 30,407 | | | | | | 475,562 | | | | | | | | | | | | 505,969 | | | | | | * | | |
Directors and executive officers as a group (11 persons) | | | | | 8,213,701 | | | | | | 6,086,164 | | | | | | 1,784,000 | | | | | | 16,083,865 | | | | | | 13.8% | | |
|